跳至主要内容
临床试验/EUCTR2007-003189-16-LT
EUCTR2007-003189-16-LT进行中(未招募)不适用

A randomized, multi center, parallel group, double-blind, placebo and formoterol controlled 14 day dose ranging trial 4 doses of indacaterol delivered via Twisthaler®, in patients with COPD.

ovartis Pharma Services AG0 个研究点目标入组 558 人开始时间: 2007年10月4日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
558

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -Male and female adults aged =40 years, who have signed an Informed Consent Form prior to initiation of any study-related procedure (which include any adjustment to their current COPD treatment – see Section 6.6.5.5.)
  • -Cooperative outpatients with a diagnosis of COPD (moderate to severe as classified by the GOLD Guidelines, 2006) and:
  • a) Smoking history of at least 10 pack years
  • b) Post-bronchodilator FEV1 < 80% and =30% of the predicted normal value.
  • c) Post-bronchodilator FEV1/FVC < 70%
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • -Pregnant women, nursing mothers, or females of childbearing potential, regardless of whether or not sexually active, if they are not using acceptable methods of contraception.
  • -Patients who have been hospitalized for an exacerbation of their airways disease within 6 weeks prior to Visit 1 or between Visit 1 and Visit 2.
  • -Patients with a history of asthma.
  • -Patients with an acute respiratory tract infection within 4 weeks prior to Visit 1, will be not allowed to enter the study.
  • -Other clinically significant conditions which may interfere with the study conduct or patient safety
  • as specified in the protocol.

研究者

相似试验

已完成
不适用
A randomized, multi center, parallel group, double-blind, placebo and formoterol controlled 14 day dose ranging trial 4 doses of indacaterol delivered via Twisthaler®, in patients with COPD.-J449 Chronic obstructive pulmonary disease, unspecifiedChronic obstructive pulmonary disease, unspecifiedJ449
PER-078-07OVARTIS BIOSCIENSES PERU S.A.,
进行中(未招募)
不适用
A randomized, multi center, parallel group, double-blind, placebo and formoterol controlled 14 day dose ranging trial 4 doses of indacaterol delivered via Twisthaler®, in patients with COPD.
EUCTR2007-003189-16-IEovartis Pharma Services AG558
进行中(未招募)
不适用
A randomized, multi center, parallel group, double-blind, placebo and formoterol controlled 14 day dose ranging trial 4 doses of indacaterol delivered via Twisthaler®, in patients with COPD.Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPD
EUCTR2007-003189-16-HUovartis Pharma Services AG558
进行中(未招募)
不适用
A randomized, multi center, parallel group, double-blind, placebo and formoterol controlled 14 day dose ranging trial 4 doses of indacaterol delivered via Twisthaler®, in patients with COPD.Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPD
EUCTR2007-003189-16-LVovartis Pharma Services AG558
进行中(未招募)
不适用
A randomized, multi center, parallel group, double-blind, placebo and formoterol controlled 14 day dose ranging trial of 4 doses of indacaterol delivered via Twisthaler®, in patients with COPD.Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPD
EUCTR2007-003189-16-GBovartis Pharma Services AG558